The evolution of chemotherapy over the last few years has been striking, now involving immunotherapy, which harnesses the immune system.  Marrying chemo-immunotherapy holds promise for improved efficacy and better long-term outcomes especially for haematological malignancies. Although palatable and promising, balancing toxicities, timing, patient selection, and understanding the delicate biology between resistance and synergy becomes intricate.  Introduction to the role players The foundation of the treatment of haematological…